AngioDynamics Reports Fiscal Second Quarter Results

On January 8, 2025, AngioDynamics, Inc. issued a press release revealing its financial performance for the fiscal second quarter that concluded on November 30, 2024. The report highlighted several significant achievements and financial outcomes, underscoring the company's operational capabilities and strategic developments.

The press release detailed AngioDynamics' financial status, reporting a pro forma revenue growth of 9% year-over-year in its MedTech segment. Notable highlights included Auryon sales reaching $13.7 million, reflecting a 22% increase from the previous year; AngioVac sales totaling $8.1 million, a remarkable 51% increase year-over-year; and AlphaVac sales at $2.5 million, marking a 33% rise on a year-over-year basis.

Additionally, AngioDynamics announced important clinical, regulatory, and market access milestones. These included the acquisition of CPT Category 1 Codes for Irreversible Electroporation (IRE) and FDA clearance for the NanoKnife device used in prostate tissue treatment. The company also mentioned its transition towards outsourced manufacturing, projecting an annual savings of $15 million by fiscal year 2027.

Improvements in profitability were also emphasized, as the company reported a pro forma Adjusted EBITDA of $3.1 million for the quarter, indicating a significant enhancement compared to the prior year. Furthermore, AngioDynamics generated operating cash flow of $2.5 million and updated its guidance concerning MedTech revenue growth and overall company profitability.

As part of its Regulation FD disclosure, AngioDynamics provided presentation slides outlining its operations and financial performance during the fiscal second quarter. The company underscored the importance of forward-looking statements and advised investors to be mindful of the risks and uncertainties associated with such projections.

This financial report portrayed AngioDynamics' commitment to transparency, offering a comprehensive overview of its financial health, strategic initiatives, and market positioning. The outlook suggested a solid trajectory toward sustained growth and operational efficiency.

Investors and stakeholders are encouraged to examine AngioDynamics' official SEC filings for a more detailed understanding and reconciliation of the reported financial data. The firm reiterated that actual performance may diverge from anticipated outcomes, highlighting the fluctuating nature of market conditions and regulatory environments.

This article presents an unbiased interpretation of AngioDynamics' recent 8-K SEC filing, aiming to provide clarity on the company's financial performance and strategic direction.

About AngioDynamics

AngioDynamics, Inc. is a medical technology firm that designs, manufactures, and sells medical, surgical, and diagnostic devices aimed at treating peripheral vascular disease, as well as oncology and surgical environments both domestically and internationally. The company offers the Auryon Atherectomy system, which is engineered to deliver an optimized wavelength, pulse width, and amplitude to effectively remove lesions while safeguarding the vessel wall's endothelium.

AngioDynamics, finance, MedTech